Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KROS
#2417
Keros Therapeutics, Inc. Common Stock
14.190
0
-3.14%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-3.14%
Monthly Change
-21.86%
6 month change
-6.03%
Cambio anual
-6.03%
Cierres anteriores
14.650
0
Open
14.190
0
Bid
Ask
Low
14.190
0
High
14.190
0
Volumen
60
Markets
Acciones
Atención Sanitaria
KROS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
23.27 M
24 M
28.54 M
35.98 M
40.56 M
—
Valuation ratios
Enterprise value
1.38 B
1.17 B
1.03 B
1.22 B
82.2 M
-583.97 M
Price to earnings ratio
—
-23.22
-11.08
-8.29
-3.17
-11.18
Price to sales ratio
—
67.92
—
8 410.96
166.94
173.86
Price to cash flow ratio
—
21.97
16.56
10.2
3.68
11.18
Price to book ratio
—
5.61
4.18
3.82
1.04
1.65
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.23
0.34
0.41
0.3
0.31
Return on equity %
0.17
0.24
0.38
0.46
0.33
0.34
Return on invested capital %
8 687.99
2 651.3
2 569.73
3 007.41
3 104.01
2 815.51
Gross margin %
—
100
—
100
100
400
Operating margin %
—
280.46
—
112.54 K
5 938.96
2 150.7
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
292.26
—
101.32 K
5 277.55
1 803.81
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
37.27
21.23
17.27
14.25
21.45
91.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.08
0
0
0.01
0.35
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
2.66
2.78
4.23
4.3
4.51
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
9.86
11.05
11.25
14.96
66.59
Net current asset value per share
—
10.78
11.32
11.79
15.73
70
Tangible book value per share
—
10.42
10.99
11.28
15.27
67.76
Working capital per share
—
10.27
10.67
10.97
15
66.85
Book value per share
—
10.42
10.99
11.28
15.27
67.76
Noticias
Keros Therapeutics suma exdirector financiero de Lyell a su consejo
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Is KROS' KER-065 the Next Breakthrough in DMD Space?
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?